Approval · Notice of Compliance 36086 · 2025
EMAVERT TABLETS: Notice of Compliance 36086
Issued October 1, 2025
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 36086
- Date
- October 1, 2025
- Company
- Felix Pharmaceuticals Pvt. Ltd.Dublin 1, Ireland
- Product type
- Veterinary
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Administrative – Additional product name
- Canadian reference product
- CERENIA (Zoetis Canada Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| EMAVERT TABLETS | 02561360 | Marketed |
| EMAVERT TABLETS | 02561379 | Marketed |
| EMAVERT TABLETS | 02561387 | Marketed |
| EMAVERT TABLETS | 02561395 | Marketed |
Medicinal ingredients
- MAROPITANT CITRATE 16 MG per TAB
- MAROPITANT CITRATE 24 MG per TAB
- MAROPITANT CITRATE 60 MG per TAB
- MAROPITANT CITRATE 160 MG per TAB